

# Neuropsicología y Envejecimiento: Una breve introducción




**RANY**<sup>TM</sup>  
H E A L T H

**Encuentro III**



Dr. Yunier Broche-Pérez, PhD.  
Asesor Científico-RANY Health



## Resultados claves:

- **ANTES** de los 40 años comienza a aparecer una divergencia en las mediciones volumétricas del **hipocampo**, siendo menores los volúmenes en personas que luego son diagnosticadas con **MCI** o **Alzheimer**.
- **Alrededor** de los 40 se muestra un patrón similar para la **amígdala** y los **ventrículos laterales**.
- El modelo indica que la **ATROFIA TEMPORAL** y el **ALARGAMIENTO VENTRICULAR** podrían ser dos eventos fisiopatológicos que caracterizan el cerebro de los pacientes con AD.

## How Does it STAC Up? Revisiting the Scaffolding Theory of Aging and Cognition

Patricia A. Reuter-Lorenz · Denise C. Park

Received: 31 July 2014 / Accepted: 7 August 2014 / Published online: 21 August 2014  
© The Author(s) 2014. This article is published with open access at Springerlink.com


**Abstract** “The Scaffolding Theory of Aging and Cognition (STAC)”, proposed in 2009, is a conceptual model of cognitive aging that integrated evidence from structural and functional neuroimaging to explain how the combined effects of adverse and compensatory neural processes produce varying levels of cognitive function. The model made clear and testable predictions about how different brain variables, both structural and functional, were related to cognitive function, focusing on the core construct of compensatory scaffolding. The present paper provides a revised model that integrates new evidence about the aging brain that has emerged since STAC was published 5 years ago. Unlike the original STAC model, STAC-r incorporates life-course factors that serve to enhance or deplete neural resources, thereby influencing the developmental course of brain structure and function, as well as cognition, over time. Life-course factors also influence compensatory processes that are engaged to meet cognitive challenge, and to ameliorate the adverse effects of structural and functional decline. The revised model is discussed in relation to recent lifespan and longitudinal data as well as emerging evidence about the effects of training interventions. STAC-r goes beyond the previous model by combining a life-span approach with a life-course approach to understand and predict cognitive status and rate of cognitive change over time.

### Introduction

Decades of behavioral research in the latter part of the 20th century characterized a variety of age-related cognitive deficits including memory problems, executive processing dysfunction and declines in speed of processing that typify normal older adults (e.g., Craik and Salthouse 2000). Despite volumes of performance data and numerous theoretical advances (e.g., Schaie et al. 1996; Schaie and Willis 2011a, b; Birren and Schaie 2005), a coherent integrated account of cognitive aging based on behavioral data alone proved to be elusive. Fortunately, the end of the last century also brought major developments in in vivo human neuroscience methods, most critically, functional and structural imaging that permitted scientists to relate neural activity and structural brain measurements to specific cognitive processing abilities (Cabeza et al. 2005). Additional and more recent advances in imaging of white matter pathways, amyloid deposits, connectivity patterns, genetic, pharmacological and other biomarkers have provided a wealth of new indices of neurophysiological status that can be integrated with behavioral performance assessments to identify the neurocognitive underpinnings of typical age-related decline (Grady 2008; Buckner et al. 2009; Bäckman et al. 2006; Raz and Lustig 2014; Bussey et al. 2012).

# Teoría Estructural del Envejecimiento Cognitivo (STAC)

- La teoría STAC concibe el funcionamiento cerebral y la cognición en un sentido tanto positivo como negativo
- Publicado por primera vez en 2009, toma en consideración los cambios que de manera normativa deben ocurrir a nivel cerebral y cognitivo, considerando además los factores que actúan como moduladores
- La primera descripción gráfica del modelo describía las variables consideradas “intervinientes” en el proceso de envejecimiento en la adultez mayor



(Reuter-Lorenz & Park, 2014)

*Cambios Cognitivos Normales  
Relacionados con el  
Envejecimiento*

*Estadios Preclínicos*

*Deterioro Cognitivo Ligero*

*Síndrome Demencial*



Esquema  
Diagnóstico  
Contemporáneo  
(Smith, 2016)

DIAGNOSTIC AND STATISTICAL  
MANUAL OF  
MENTAL DISORDERS,

FIFTH EDITION

DSM-5™

New School Library





American  
Psychiatric  
Publishing





Washington, DC  
London, England

## Criterios Diagnósticos

1. Evidencia de declive cognitivo en uno o más dominios, obtenido a partir a partir del estudio del paciente, un informante, o un especialista, o luego de evaluación objetiva;
2. Preservación de la independencia funcional;
3. El deterioro no se limita únicamente a episodios de delirium;
4. El deterioro no se explica por la presencia de otras condiciones, por ejemplo , depresión;
5. Ausencia de Demencia



**Cinco dimensiones  
del Modelo de  
Bienestar de Hettler  
(2015)**




# Memoria y Aprendizaje

Modalidades de memoria


Memoria a corto plazo (MCP)

Memoria a largo plazo (MLP)

# Memoria y Aprendizaje



# Modelo de Memoria de Trabajo (Baddeley & Hitch, 1974)




# Modelo de Memoria de Trabajo (Baddeley & Hitch, 1974)




# The episodic buffer: a new component of working memory?

Alan Baddeley


In 1974, Baddeley and Hitch proposed a three-component model of working memory. Over the years, this has been successful in giving an integrated account not only of data from normal adults, but also neuropsychological, developmental and neuroimaging data. There are, however, a number of phenomena that are not readily captured by the original model. These are outlined here and a fourth component to the model, the episodic buffer, is proposed. It comprises a limited capacity system that provides temporary storage of information held in a multimodal code, which is capable of binding information from the subsidiary systems, and from long-term memory, into a unitary episodic representation. Conscious awareness is assumed to be the principal mode of retrieval from the buffer. The revised model differs from the old principally in focussing attention on the processes of integrating information, rather than on the isolation of the subsystems. In doing so, it provides a better basis for tackling the more complex aspects of executive control in working memory.



# Modelo de Memoria de Trabajo (Baddeley, 2000)



# Memoria y Aprendizaje



# Dos formas de memoria a LP

## Explícita (Declarativa)

Episódica

Semántica

Lobúlo temporal medial

## Implícita (No declarativa)

Priming

Procedimientos

Aprendizaje asociativo:  
condicionamiento clásico y operante

Aprendizaje no asociativo:  
habituaación y sensibilización

Neocortex

Estriado

Respuesta emocional


Músculos y Esqueleto

Amígdala

Cerebelo

Vías Reflejas

## Aplysia





**Eric Kandel**



**Brenda Milner**



**Paciente H.M.  
(Henry Gustav Molaison)**




Alteraciones en la Memoria de Trabajo

Dificultades en el Aprendizaje

Alteraciones en la Memoria a Largo Plazo

Desintegración de la personalidad, el comportamiento



La alteración de circuitos neurales, lesiones focales y alteraciones del neurodesarrollo pueden afectar considerablemente los procesos de aprendizaje y memoria

## Neurodegeneration




OPEN ACCESS


REVIEW

# Neuronal network disintegration: common pathways linking neurodegenerative diseases


Rebekah M Ahmed,<sup>1,2</sup> Emma M Devenney,<sup>1,2</sup> Muireann Irish,<sup>2,3</sup> Arne Ittner,<sup>4</sup> Sharon Naismith,<sup>5</sup> Lars M Ittner,<sup>4</sup> Jonathan D Rohrer,<sup>6</sup> Glenda M Halliday,<sup>2</sup> Andrew Eisen,<sup>7</sup> John R Hodges,<sup>2</sup> Matthew C Kiernan<sup>1</sup>



**Figure 1** Clinical and pathological overlap in neurodegeneration: showing overlap at both a phenotypic and pathological level between multiple neurodegenerative conditions.



**Regiones cerebrales claves para la memoria episódica**



**Robin Williams**  
(1951 – 2014)



**Ronald Reagan**  
(1911 – 2004)



**Rosa Parks**  
(1913 – 2005)

# DEMENCIA

Término “paraguas” empleado para describir un grupo de condiciones (más de 100) caracterizadas por alteraciones de la memoria, el comportamiento y el pensamiento.

## Enfermedad de Parkinson

5% de todos los casos de demencia.

## Demencia Frontotemporal

5% de todos los casos de demencia.

## Demencia Vascular


Segunda forma más frecuente de demencia (20% del total de casos).

## Enfermedad de Alzheimer

50-70% de todos los casos de demencia.

## Demencia de los Cuerpos de Lewy

15% de todos los casos de demencia.



Estimados de prevalencia por regiones del mundo

World Alzheimer Report 2015




46, 800, 000  
Personas padecen demencia a nivel mundial




En 2015 se diagnosticaron **9.9** millones de nuevos casos  
**UN CASO CADA 3 SEGUNDOS**




Este valor se duplica cada 20 años



2015



2030




2050

Tendencias  
Actuales y  
Pronósticos a  
Largo Plazo

World Alzheimer Report 2015

## CRECIMIENTO DEL NÚMERO DE PERSONAS CON DEMENCIA EN PAÍSES CON ALTOS INGRESOS (PIA) E INGRESOS BAJOS Y MEDIOS (PIBM)



PIBM PIA

World Alzheimer Report 2015

# LA DEMENCIA EN EL CARIBE

Las cifras se presentan en miles.

País	2010	2030	2050	Incremento (%)
Cuba	150	273	421	181
República Dominicana	54	125	241	346
Puerto Rico	48	79	109	127
Haití	22	42	86	291
Guadalupe	5	9	16	220
Guyana Francesa	1	2	5	400
<b>Total</b>	<b>280</b>	<b>530</b>	<b>878</b>	<b>449</b>








Informe ADI/Bupa: La demencia en América: El coste y la prevalencia del Alzheimer y otros tipos de demencia. Octubre 2013.

## Plaquetas y Ovillos: Los marcadores de la EA

*El cerebro de las personas con EA son abundantes en dos estructuras anormales:*

- Plaquetas beta-amiloide (placas seniles): depocisiones densas de proteínas y material celular que se acumula fuera del axón celular.
- Ovillos neurofibrilares: fibras entrelazadas que se forman dentro de la neurona.






## Placas beta-amiloides


La Proteína precursora de Amiloide (APP) es el precursor de las plaquetas beta-amiloides

1. APP se muestra como un filamento adherido a la membrana.
2. Las enzimas cortan el APP en fragmentos de proteínas, incluyendo el beta-amiloide.
3. Los fragmentos beta-amiloides se agrupan para formar las plaquetas.


**Este mecanismo es extra-celular...**



- Las neuronas tienen una estructura que le da soporte que se denominan microtúbulos.
- Una proteína denominada tau estabiliza los microtúbulos.
- En la EA la tau cambia y los microtúbulos colapsan y forman los ovillos.



# *Genes y Demencia*



**James D. Watson & Francis Crick**  
Discoverers of DNA structure

# ***APOE* is a major susceptibility gene for Alzheimer's disease**

**Allen D Roses and Ann M Saunders**

Duke University Medical Center, Durham, USA

The initial report on *APOE* as a susceptibility gene for late-onset Alzheimer's disease was presented a little more than two years ago. During the past year, several significant events have given added impetus to research into Alzheimer's. The association of increased allele frequency of *APOE4* with Alzheimer's disease has been reproduced in several dozen laboratories around the world. The protective effect of the *APOE2* allele has been reported and also rapidly verified. No evidence exists to support the notion of linkage disequilibrium with any nearby locus on chromosome 19. The neuropathological demonstration of apolipoprotein E (apoE) within neuronal cytoplasm in a location suitable for proposed interaction with microtubule-associated protein tau and MAP2c has introduced a new view of neuronal neurobiology. As apoE is not known to be expressed in neurons, its relationship with cellular receptors, such as the low-density lipoprotein related receptor, and the mechanism of intracellular trafficking are now important research problems. The role of apoE as a metabolic co-factor in neuronal metabolism presents new possibilities for neuronal mechanisms of

***APOE* is a major susceptibility gene for Alzheimer's disease**

Inheritance of one or two *APOE4* alleles increases the risk of Alzheimer's disease by about threefold for each *APOE4* allele dose

disease was presented a little more than two years ago. During the past year, several significant events have given added impetus to research into

***“Heredar uno o dos alelos del APOE 4 incrementa el riesgo de Enfermedad de Alzheimer alrededor de tres veces...”***

microtubule-associated protein tau and MAP2C has introduced a new view of neuronal neurobiology. As apoE is not known to be expressed in neurons, its relationship with cellular receptors, such as the low-density lipoprotein related receptor, and the mechanism of intracellular trafficking are now important research problems. The role of apoE as a metabolic co-factor in neuronal metabolism presents new possibilities for neuronal mechanisms of

## Genetic Studies of Human Apolipoproteins. X. The Effect of the Apolipoprotein E Polymorphism on Quantitative Levels of Lipoproteins in Nigerian Blacks

To date, Nigerian blacks have the highest observed frequency of the *APO E\*4* allele in world populations

### Summary

*“Hasta la fecha, los nigerianos tienen la frecuencia observada más alta del alelo APOE 4 en la población mundial...”*

terol and low-density lipoprotein cholesterol by 9.19 mg/dl and 11.11 mg/dl, respectively. The average excesses of the *APO E\*4* allele are to increase total cholesterol and low-density lipoprotein cholesterol by

# Alzheimer's disease: the cholesterol connection

Luigi Puglielli<sup>1,2</sup>, Rudolph E. Tanzi<sup>2</sup> and Dora M. Kovacs<sup>1,2</sup>

---

<sup>1</sup> *Neurobiology of Disease Laboratory and* <sup>2</sup> *Genetics and Aging Research Unit, CAGN, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, USA*

*Correspondence should be addressed to D.M.K. (kovacs@helix.mgh.harvard.edu)*

**A hallmark of all forms of Alzheimer's disease (AD) is an abnormal accumulation of the  $\beta$ -amyloid protein ( $A\beta$ ) in specific brain regions. Both the generation and clearance of  $A\beta$  are regulated by cholesterol. Elevated cholesterol levels increase  $A\beta$  in cellular and most animals models of AD, and drugs that inhibit cholesterol synthesis lower  $A\beta$  in these models. Recent studies show that not only the total amount, but also the distribution of cholesterol within neurons, impacts  $A\beta$  biogenesis. The identification of a variant of the apolipoprotein E (*APOE*) gene as a major genetic risk factor for AD is also consistent with a role for cholesterol in the pathogenesis of AD. Clinical trials have recently been initiated to test whether lowering plasma and/or neuronal cholesterol levels is a viable strategy for treating and preventing AD. In this review, we describe recent findings concerning the molecular mechanisms underlying the cholesterol–AD connection.**

# Alzheimer's disease: the cholesterol connection

ApoE is one of the major apolipoproteins in the plasma and the principal cholesterol carrier protein in the brain.

Correspondence should be addressed to D.M.K. ([kovacs@helix.mgh.harvard.edu](mailto:kovacs@helix.mgh.harvard.edu))

***“APOE es una de las mayores apolipoproteínas en el plasma y el principal transportador de colesterol en el cerebro...”***

A hall  
proteín  
lesterol  
that in  
total a  
identif

also consistent with a role for cholesterol in the pathogenesis of AD. Clinical trials have recently been initiated to test whether lowering plasma and/or neuronal cholesterol levels is a viable strategy for treating and preventing AD. In this review, we describe recent findings concerning the molecular mechanisms underlying the cholesterol–AD connection.

## Genetic Studies of Human Apolipoproteins. X. The Effect of the Apolipoprotein E Polymorphism on Quantitative Levels of Lipoproteins in Nigerian Blacks

*“Hasta la fecha, los nigerianos tienen la frecuencia observada más alta del alelo APOE 4 en la población mundial, pero sus ajustes medios de en el nivel de colesterol se encuentra entre los **más bajos** entre los estudios que relaciona el colesterol y el APOE...esto podría ser a causa de su **dieta** baja en grasa animal”*

are .027, .677, and .296. The effect of APO E polymorphism is significant only on total cholesterol and low-density lipoprotein cholesterol. The average excesses of the APO E\*2 allele are to lower total cholesterol and low-density lipoprotein cholesterol by 9.19 mg/dl and 11.11 mg/dl, respectively. The average excesses of the APO E\*4 allele are to increase total cholesterol and low-density lipoprotein cholesterol by

Irma-Leena Notkola<sup>a</sup>

Raimo Sulka

Juha Pekka

Timo Erkin

Christian E

Paula Kivin

Jaakko Tuc

Aulikki Nis

## Serum Total Cholesterol.

**“En Nigeria, donde la frecuencia del *APOE 4* es alta, pero los niveles de *colesterol* son bajos, la Enfermedad de Alzheimer *suele ser rara*. Sin embargo, los afroamericanos tienen una *alta prevalencia de Alzheimer* tanto como los demás norteamericanos. La asociación entre el genotipo *APOE* y el *colesterol* parece ser un resultado del *estilo de vida occidental....*”**

<sup>a</sup> Department of

General Pract

Kuopio,

Departments

<sup>b</sup> Environment

<sup>c</sup> Biochemistry

<sup>d</sup> Epidemiology

Promotion, N

Health Institu

<sup>e</sup> Department of

University of

nd

ociated with

serum total

however, the

a cholesterol


we examined

pathogenesis

aged 70–89

of the Seven

level (mean



**Bruce Lipton, PhD**

- El paradigma tradicional plantea la idea de que la biología es controlada por la actividad de los genes.
- Bruce Lipton, desarrolló un grupo de experimentos y demostró que la actividad de los genes no es solo activada o inhibida por sus información intrínseca , sino además por la información del ambiente

# Alzheimer disease risk genes: 29 and counting

Lars Bertram and Rudolph E. Tanzi 

The risk of Alzheimer disease is substantially influenced by genetic factors. A new genome-wide association study of more than 600,000 individuals identifies nine novel Alzheimer disease risk genes, raising the total count of independent risk loci to 29.

Refers to Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer disease risk. *Nat. Genet.* <https://doi.org/10.1038/s41588-018-0311-9> (2019).

Alzheimer disease (AD) is a debilitating neurodegenerative disorder that is characterized by progressive decline in cognitive functioning and ultimately leads to dementia and death. Pathogenetically, AD is triggered by


more than eightfold greater than that of the 2013 GWAS by accumulating the genetic data of ~635,000 individuals. This vast increase in number enabled the identification of nine novel AD risk loci, increasing the current total

At baseline, UKB participants were aged between 49 years and 69 years, and were therefore mostly too young to have developed AD, incidence of which peaks after the age of

***“Genes de riesgo para la Enfermedad de Alzheimer: 29 y contando”***

posed<sup>8</sup> to be a valid approximation of future AD status in UKB individuals for whom genotype data were available but who had not (yet) developed AD themselves.

Second, Jansen et al.<sup>4</sup> used an impressive array of computational tools with the aim of integrating high-resolution transcriptomics and epigenomics data to aid the molecular and functional interpretation of their results. These analyses revealed that most DNA variants associated with AD are located in non-coding portions of the genome, especially in regions that have effects on gene transcription. This finding is in line with



# Neuropsicología y Envejecimiento: Una breve introducción



**RANY**<sup>TM</sup>  
H E A L T H

**Encuentro III**



Dr. Yunier Broche-Pérez, PhD.  
Asesor Científico-RANY Health